{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T10:11:26Z","timestamp":1648548686951},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.2515\/therapie\/2011075","type":"journal-article","created":{"date-parts":[[2011,12,20]],"date-time":"2011-12-20T13:18:04Z","timestamp":1324387084000},"page":"527-540","source":"Crossref","is-referenced-by-count":4,"title":["Campagne nationale de vaccination contre la grippe A (H1N1)v : suivi national de pharmacovigilance"],"prefix":"10.1016","volume":"66","author":[{"given":"Genevi\u00e8ve","family":"Durrieu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Caillet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Lacroix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Jacquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angeline","family":"Faucher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sh\u00e9h\u00e9razade","family":"Ouaret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agn\u00e8s","family":"Sommet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Christine","family":"Perault-Pochat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Kreft-Ja\u00efs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Castot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Damase-Michel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Louis","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.2515\/therapie\/2011075_bb0005","author":"European medicines agency (EMA)"},{"key":"10.2515\/therapie\/2011075_bb0010","author":"Afssaps"},{"key":"10.2515\/therapie\/2011075_bb0015","unstructured":"Afssaps. T\u00e9l\u00e9d\u00e9claration par les professionnels de sant\u00e9 des \u00e9v\u00e9nements ind\u00e9sirables graves susceptibles d\u2019\u00eatre dus aux vaccins ou aux m\u00e9dicaments antiviraux. http:\/\/www.afssaps.fr\/."},{"key":"10.2515\/therapie\/2011075_bb0020","unstructured":"Afssaps. Vaccins et antiviraux contre le virus grippal A (H1N1)v. Fiche PATIENT de d\u00e9claration des \u00e9v\u00e9nements ind\u00e9sirables. http:\/\/www.afssaps.fr\/var\/afssaps_site\/storage\/original\/application\/923e412bb8a3227e36372b86775dd303.pdf"},{"key":"10.2515\/therapie\/2011075_bb0025","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis, and management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"key":"10.2515\/therapie\/2011075_bb0030","unstructured":"Medical dictionary of regulatory activities, MedDRA version 13.0."},{"key":"10.2515\/therapie\/2011075_bb0035","first-page":"111","article-title":"Imputabilit\u00e9 des effets inattendus ou toxiques des m\u00e9dicaments","volume":"40","author":"Begaud","year":"1985","journal-title":"Th\u00e9rapie"},{"key":"10.2515\/therapie\/2011075_bb0040","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1002\/ana.410270707","article-title":"Assessment of current diagnostic criteria for Guillain-Barr\u00e9 syndrome","volume":"27","author":"Asbury","year":"1990","journal-title":"Ann Neurol"},{"key":"10.2515\/therapie\/2011075_bb0045","author":"Afssaps"},{"key":"10.2515\/therapie\/2011075_bb0050","series-title":"Ateliers nationaux de pharmacovigilance (Deauville 1997)","first-page":"9","article-title":"Quelle pharmacovigilance pour les vaccins ?","author":"Loupi","year":"1998"},{"key":"10.2515\/therapie\/2011075_bb0055","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2515\/therapie:2007048","article-title":"Quelle pharmacovigilance pour les vaccins","volume":"62","author":"Le Lou\u00ebt","year":"2007","journal-title":"Th\u00e9rapie"},{"issue":"8","key":"10.2515\/therapie\/2011075_bb0060","first-page":"1489","article-title":"Pharmacovigilance des vaccins contre l\u2019h\u00e9patite B. Discussion : les vaccinations","volume":"187","author":"Imbs","year":"2003","journal-title":"Bull Acad Natl Med"},{"key":"10.2515\/therapie\/2011075_bb0065","doi-asserted-by":"crossref","first-page":"8157","DOI":"10.1016\/j.vaccine.2010.09.096","article-title":"Population and risk group uptake of H1N1 influenza vaccine in mainland France 2009-2010: results of a national vaccination campaign","volume":"28","author":"Bone","year":"2010","journal-title":"Vaccine"},{"key":"10.2515\/therapie\/2011075_bb0070","series-title":"Actualisation de l\u2019avis relatif aux recommandations sur l\u2019utilisation des vaccins pand\u00e9miques dirig\u00e9s contre le virus grippal A(H1N1)v","year":"2009"},{"key":"10.2515\/therapie\/2011075_bb0075","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1016\/j.vaccine.2009.01.125","article-title":"Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring","volume":"27","author":"Vellozzi","year":"2009","journal-title":"Vaccine"},{"key":"10.2515\/therapie\/2011075_bb0080","series-title":"European medicines agency starts review of Pandemrix","year":"2010"},{"key":"10.2515\/therapie\/2011075_bb0085","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2165\/00002018-200932040-00005","article-title":"Vaccines and Guillain-Barre syndrome","volume":"32","author":"Haber","year":"2009","journal-title":"Drug Saf"},{"key":"10.2515\/therapie\/2011075_bb0090","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(09)61877-8","article-title":"Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines","volume":"374","author":"Black","year":"2009","journal-title":"The Lancet"},{"key":"10.2515\/therapie\/2011075_bb0095","first-page":"10","article-title":"Number of spontaneous reports of Guillain-Barr\u00e9 syndrome after flu A(H1N1) vaccination versus expected number in France","volume":"33","author":"Saussier","year":"2010","journal-title":"Drug Saf"},{"key":"10.2515\/therapie\/2011075_bb0100","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.neurol.2009.04.003","article-title":"Epidemiology of multiple sclerosis: the special situation in France","volume":"165","author":"Fromont","year":"2009","journal-title":"Rev Neurol"},{"key":"10.2515\/therapie\/2011075_bb0110","first-page":"420","article-title":"Social pharmacology: a new topic in clinical pharmacology","volume":"57","author":"Montastruc","year":"2002","journal-title":"Th\u00e9rapie"},{"key":"10.2515\/therapie\/2011075_bb0115","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00228-005-0925-6","article-title":"\u201cMedicamentation\u201d of society, nondiseases and non-medications: a point of view from social pharmacology","volume":"61","author":"Mbongue","year":"2005","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716308095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716308095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T07:35:43Z","timestamp":1554276943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716308095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0040595716308095"],"URL":"https:\/\/doi.org\/10.2515\/therapie\/2011075","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}